Intel predicts widespread adoption of AI in healthcare
July 11, 2018
US healthcare leaders expect the widespread adoption of artificial intelligence by 2023, according to an Intel survey. But trust is still a barrier.
The study, conducted in partnership with Convergys Analytics, surveyed 200 US healthcare decision-makers in April 2018 on their attitudes about AI and perceived barriers to adoption in the industry.
AI today is already being applied behind the scenes to detect drug interactions and predict which patients are most at risk for readmissions or experiencing a hospital-acquired condition. But the promise of AI is much greater: it has the potential to improve clinical effectiveness, reduce cost and increase the quality of patient care.
The study found that among the respondents whose organisations use AI, clinical use (77 per cent) outpaces operational (41 per cent) and financial use (26 per cent). Additionally, the benefits of AI are widely recognised, with 91 per cent of respondents believing it will provide predictive analytics for early intervention, 88 per cent saying the technology will improve care, and 83 per cent saying it will improve accuracy of medical diagnoses.
However, trust remains the biggest obstacle to implementing AI in healthcare. More than one-third of those surveyed say patients won't trust AI to play an active role in their healthcare, and 30 per cent assumed that clinicians won't trust it either – they fear fatal error is the largest barrier to adoption.
To realise the potential of AI in healthcare, Intel says it is imperative that the technology industry work with partners in healthcare to start building trust now by:
- Addressing the black box perception of AI;
- Leaning into areas where clinicians are ready for change and fatal error is less likely;
- Highlighting benefits for all involved; and
- Providing input into the regulatory process.